Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding

Molecular Cell

Volumn 12, Issue 5, 2003, Pages 1213-1224

  Feldman, Douglas E ^a   Spiess, Christoph ^a   Howard, Daniel E ^a,b   Frydman, Judith ^a  

^a STANFORD UNIVERSITY   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN; POLYPEPTIDE; PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CARCINOGENESIS; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; POINT MUTATION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

EUKARYOTA;

EID: 0345708112     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00423-4     Document Type: Article

References (38)

1. Aso T., Lane W.S., Conaway J.W., Conaway R.C. Elongin (SIII). a multisubunit regulator of elongation by RNA polymerase II Science. 269:1995;1439-1443.
2. Béroud C., Joly D., Gallou C., Staroz F., Orfanelli M.T., Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 26:1998;256-258.
3. Bukau B., Horwich A.L. The Hsp70 and Hsp60 chaperone machines. Cell. 92:1998;351-366.
4. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., Lane D.P., Fersht A.R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA. 94:1997;14338-14342.
5. Camasses A., Bogdanova A., Shevchenko A., Zachariae W. The CCT chaperonin promotes activation of the anaphase-promoting complex through the generation of functional Cdc20. Mol Cell. 12:2003;87-100.
6. Clifford S.C., Maher E.R. von Hippel-Lindau disease. clinical and molecular perspectives Adv. Cancer Res., Vol. 82; 82:2001;85-105.
7. Dobson C.M. The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:2001;133-145.
8. Duan D.R., Humphrey J.S., Chen D.Y., Weng Y., Sukegawa J., Lee S., Gnarra J.R., Linehan W.M., Klausner R.D. Characterization of the VHL tumor suppressor gene product. localization, complex formation, and the effect of natural inactivating mutations Proc. Natl. Acad. Sci. USA. 92:1995;6459-6463. a.
9. Duan D.R., Pause A., Burgess W.H., Aso T., Chen D.Y., Garrett K.P., Conaway R.C., Conaway J.W., Linehan W.M., Klausner R.D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 269:1995;1402-1406. b.
10. Dunn A.Y., Melville M.W., Frydman J. Cellular substrates of the eukaryotic chaperonin TRiC/CCT. J. Struct. Biol. 135:2001;176-184.
11. Ellis R.J. Macromolecular crowding. an important but neglected aspect of the intracellular environment Curr. Opin. Struct. Biol. 11:2001;114-119.
12. Farr G.W., Furtak K., Rowland M.B., Ranson N.A., Saibil H.R., Kirchhausen T., Horwich A.L. Multivalent binding of nonnative substrate proteins by the chaperonin GroEL. Cell. 100:2000;561-573.
13. Feldman D.E., Thulasiraman V., Ferreyra R.G., Frydman J. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol. Cell. 4:1999;1051-1061.
14. Ferreyra R.G., Frydman J. Purification of the cytosolic chaperonin TRiC from bovine testis. Schneider C. Chaperonin Protocols. 2000;Humana Press, Totowa, NJ. 153-160.pp.
15. Frydman J. Folding of newly translated proteins in vivo. the role of molecular chaperones Annu. Rev. Biochem. 70:2001;603-647.
16. Frydman J., Hartl F.U. Principles of chaperone-assisted protein folding. differences between in vitro and in vivo mechanisms Science. 272:1996;1497-1502.
17. Gavin A.C., Bosche M., Krause R., Grandi P., Marzioch M., Bauer A., Schultz J., Rick J.M., Michon A.M., Cruciat C.M., et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature. 415:2002;141-147.
18. Hansen W.J., Ohh M., Moslehi J., Kondo K., Kaelin W.G., Welch W.J. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 22:2002;1947-1960.
19. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol. from nascent chain to folded protein Science. 295:2002;1852-1858.
20. Hayer-Hartl M.K., Ewbank J.J., Creighton T.E., Hartl F.U. Conformational specificity of the chaperonin GroEL for the compact folding intermediates of alpha-lactalbumin. EMBO J. 13:1994;3192-3202.
21. Ho Y., Gruhler A., Heilbut A., Bader G.D., Moore L., Adams S.L., Millar A., Taylor P., Bennett K., Boutilier K., et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature. 415:2002;180-183.
22. Hynes G.M., Willison K.R. Individual subunits of the eukaryotic cytosolic chaperonin mediate interactions with binding sites located on subdomains of beta-actin. J. Biol. Chem. 275:2000;18985-18994.
23. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682.
24. Leroux M.R., Hartl F.U. Protein folding. versatility of the cytosolic chaperonin TRiC/CCT Curr. Biol. 10:2000;R260-R264.
25. Llorca O., Martin-Benito J., Ritco-Vonsovici M., Grantham J., Hynes G.M., Willison K.R., Carrascosa J.L., Valpuesta J.M. Eukaryotic chaperonin CCT stabilizes actin and tubulin folding intermediates in open quasi-native conformations. EMBO J. 19:2000;5971-5979.
26. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
27. McCormack E.A., Rohman M.J., Willison K.R. Mutational screen identifies critical amino acid residues of beta-actin mediating interaction between its folding intermediates and eukaryotic cytosolic chaperonin CCT. J. Struct. Biol. 135:2001;185-197.
28. Melville M.W., McClellan A.J., Meyer A.S., Darveau A., Frydman J. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol. Cell. Biol. 23:2003;3141-3151.
29. Ohh M., Park C.W., Ivan N., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:2000;423-427.
30. Pappenberger G., Wilsher J.A., Roe S.M., Counsell D.J., Willison K.R., Pearl L.H. Crystal structure of the CCTgamma apical domain. implications for substrate binding to the eukaryotic cytosolic chaperonin J. Mol. Biol. 318:2002;1367-1379.
31. Pause A., Lee S., Worrell R.A., Chen D.Y., Burgess W.H., Linehan W.M., Klausner R.D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA. 94:1997;2156-2161.
32. Plaxco K.W., Simons K.T., Baker D. Contact order, transition state placement and the refolding rates of single domain proteins. J. Mol. Biol. 277:1998;985-994.
33. Radford S.E., Dobson C.M. From computer simulations to human disease. emerging themes in protein folding Cell. 97:1999;291-298.
34. Richardson J.S., Richardson D.C. Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc. Natl. Acad. Sci. USA. 99:2002;2754-2759.
35. Rommelaere H., De Neve M., Melki R., Vandekerckhove J., Ampe C. The cytosolic class II chaperonin CCT recognizes delineated hydrophobic sequences in its target proteins. Biochemistry. 38:1999;3246-3257.
36. Smith T.F., Gaitatzes C., Saxena K., Neer E.J. The WD repeat. a common architecture for diverse functions Trends Biochem. Sci. 24:1999;181-185.
37. Stebbins C.E., Kaelin W.G. Jr., Pavletich N.P. Structure of the VHL-ElonginC-ElonginB complex. implications for VHL tumor suppressor function Science. 284:1999;455-461.
38. Thulasiraman V., Yang C.F., Frydman J. In vivo newly translated polypeptides are sequestered in a protected folding environment. EMBO J. 18:1999;85-95.